Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 01, 2015 2:42 PM ET

Biotechnology

Company Overview of AlphaVax, Inc.

Company Overview

AlphaVax, Inc. produces vaccines for infectious disease prevention and cancer immunotherapy. Its alphavccine candidates targeting human cytomegalovirus, influenza A virus, or HIV-1 are in clinical trials. The company’s products also include AVX901, a HER2-VRP vaccine for a Phase I study in advanced and metastatic breast cancer. Its alphavaccine technology is based on its replicon vector platform derived from attenuated strains of the alphavirus, Venezuelan equine encephalitis virus. The company’s alphavaccine applications include prophylactic vaccines, therapeutic vaccines, tumor immunotherapy, and biodefense. Its products are used in various cancer treatments, such as colon cancer, breast c...

2 Triangle Drive

P.O. Box 110307

Research Triangle Park, NC 27709-0307

United States

Founded in 1997

Phone:

919-595-0400

Fax:

919-595-0401

Key Executives for AlphaVax, Inc.

Chief Financial Officer
Corporate Counsel
Vice President of Business Development
Senior Director of Quality Assurance
Chairman of CMV Advisory Board and Vice President of Research
Compensation as of Fiscal Year 2014.

AlphaVax, Inc. Key Developments

Harrisvaccines Secures Exclusive Rights from AlphaVax, Inc. to Develop RNA Particle Vaccines for All Diseases in Companion Animals

Harrisvaccines announced it has expanded its exclusive license agreement with AlphaVax, Inc. to include all companion animals diseases, in addition to all livestock animal diseases (swine, cattle, horses, poultry, and farmed aquatic animals). This announcement significantly expands the Harrisvaccines product portfolio, transforming it from a primarily production livestock-focused company to a full-service veterinary animal health company, developing vaccines for animals large and small. Harrisvaccines will begin its work in the companion animal realm by developing vaccines for a variety of respiratory diseases in dogs. Harrisvaccines' RNA Particle (RP) Platform technology utilizes a genetic sequence of specific viruses, which can be submitted electronically, to create a vaccine. Harrisvaccines can use this technology to develop strain-specific vaccines in just a matter of weeks, allowing for rapid response to disease outbreaks. As diseases are constantly evolving, this is crucial to containment and eradication efforts.

Similar Private Companies By Industry

Company Name Region
Research And Diagnostic Systems, Inc. United States
Cresco Labs, LLC United States
Concortis Biosystems, Corp. United States
EndoVention Inc. United States
PhytaGro Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AlphaVax, Inc., please visit www.alphavax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.